Search results
Results From The WOW.Com Content Network
In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included the rights to commercialize the drug designed to treat hypertrophic cardiomyopathies, aficamten, in China and certain neighboring regions. Products. Omecamtiv mecarbil is a cardiac muscle activator for the potential treatment of heart failure.
Shares of the San Francisco-based Cytokinetics surged over 80% to touch a more than a 19-year high of $83.82, on track to add as much as $3.74 bi Cytokinetics heart drug succeeds in closely ...
(Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
Omecamtiv mecarbil. Omecamtiv mecarbil ( INN [1] ), previously referred to as CK-1827452, is a cardiac-specific myosin activator. It is an experimental drug being studied for a potential role in the treatment of left ventricular systolic heart failure. [2] Systolic heart failure involves a loss of effective actin -myosin cross bridges in the ...
The Food and Drug Administration on Friday approved Pfizer ’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S. The ...
Amgen Inc. Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. [3] [4] One of the world's largest independent biotechnology companies, As of 2022, Amgen has approximately 24,000 staff in total. [5] The name "AMGen" is a portmanteau of the ...
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19, [1] [2] triple negative breast cancer, [3] and HIV infection. [4] The United States Food and Drug Administration has ...
Novartis may attempt to pursue a deal for Cytokinetics in the future or a different suitor may acquire the company, the person said. On Monday, Reuters reported that Novartis is in the lead to ...